Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CAP-IT Clear all

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more

Conditions: Bipolar Disorder
Interventions: MCN36 (nutritional supplement), Placebo; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions: Elinzanetant (BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dementia, Alzheimer Type
Interventions: Xanamem™, Placebo (for Xanamem™); Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Poway, California + 11 more

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions: Bright blue-green light using light visor cap, Dim red light using light visor cap, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Digital foot candle datalogging light meter (Extech Instrument, Model SDL400), Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA), Horne-Ostberg Morningness-Eveningness Questionnaire, Daily Fatigue and Sleep Log; Other · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Covid19
Interventions: mQFPD, organic brown rice; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • San Diego, California

Conditions: Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions: Dry Needling, Sham Dry Needling; Device · Other
Lead sponsor: Army-Baylor University Doctoral Program in Physical Therapy; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Aphthous Stomatitis
Interventions: multivitamin; Dietary Supplement
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Type 1 Diabetes
Interventions: Autologous UCB, Omega 3 FA, Vitamin D; Biological · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions: Enzalutamide, Trastuzumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Interventions: MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole; Drug
Lead sponsor: Metagen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Naples, Florida • Boston, Massachusetts • New York, New York

Conditions: Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions: Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys; Other · Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Fabry Disease
Interventions: Lucerastat; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Birmingham, Alabama • Oakland, California • Gainesville, Florida + 5 more

Conditions: Marijuana Abuse
Interventions: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions: Dimethyl fumarate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy, Elderly
Interventions: 2g Centella asiatica water extract product, 4g Centella asiatica water extract product; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions: topical gemcitabine hydrochloride, therapeutic conventional surgery; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Dopamine Beta Hydroxylase (DBH) Deficiency
Interventions: droxidopa; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anterior Cruciate Ligament Reconstruction, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Hip Arthroscopy
Interventions: Visualization training with neurofeedback, Standard post-surgical rehabilitation therapy; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions: therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Olfactory Dysfunction, Smell Loss, Anosmia, Hyposmia
Interventions: Sudoku Puzzles, ScentCare (Olfactory Training Device); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hyperprolactinemia
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Lung Diseases, Lung Cancer, Protection Against
Interventions: Curcumin C3 complex®, Lovaza®, Placebo; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Bright Light on Fatigue in Women Being Treated for Breast Cancer

RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling

Prevention of Recurrent Aphthous Stomatitis Using Vitamins

Cord Blood Plus Vitamin D and Omega 3s in T1D

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

Marijuana Drug Discrimination and Self-Administration

Dimethyl Fumarate for Obstructive Sleep Apnea

Pharmacokinetics of Centella Asiatica in the Elderly

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

Long Term Treatment With L-DOPS

Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers